Lexeo Therapeutics is a clinical-stage genetic medicine company focused on cardiovascular gene therapies. Its lead candidate, LX2006 (AAVrh10-based), targets Friedreich ataxia cardiomyopathy and is in Phase 1/2 trials. LX2020 targets PKP2-arrhythmogenic cardiomyopathy, also in Phase 1/2. Additional pipeline candidates include LX2021 (Cx43, DSP cardiomyopathy), LX2022 (TNNI3, hypertrophic cardiomyopathy), and LX1001 (APOE4-associated Alzheimer's disease). The company uses AAVrh10 vectors and a proprietary Sf9 baculovirus manufacturing platform.
expected 2026-12-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001193125-26-132085 | EDGAR | 110K words |
| 2025-03-24 | 2024-12-31 | 0000950170-25-043486 | EDGAR | 110K words |
| 2024-03-11 | 2023-12-31 | 0000950170-24-028941 | EDGAR | 114K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001193125-26-345724 | EDGAR | 77K words |
| 2025-11-05 | 2025-09-30 | 0001193125-25-265757 | EDGAR | 78K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108427 | EDGAR | 75K words |
| 2025-05-12 | 2025-03-31 | 0000950170-25-068536 | EDGAR | 71K words |
| 2024-11-13 | 2024-09-30 | 0000950170-24-125943 | EDGAR | 72K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095057 | EDGAR | 71K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056247 | EDGAR | 68K words |
| 2023-12-11 | 2023-09-30 | 0000950170-23-069192 | EDGAR | 76K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-22 | 0001193125-26-397221 | EDGAR | 2K words |
| 2026-08-12 | 0001193125-26-345722 | EDGAR | 2K words |
| 2026-03-30 | 0001193125-26-131792 | EDGAR | 2K words |
| 2026-02-05 | 0001193125-26-039425 | EDGAR | 1K words |
| 2026-01-27 | 0001193125-26-023339 | EDGAR | 1K words |
| 2026-01-12 | 0001193125-26-010091 | EDGAR | 1K words |
| 2025-11-05 | 0001193125-25-265755 | EDGAR | 2K words |
| 2025-10-17 | 0001193125-25-242652 | EDGAR | 1K words |
| 2025-10-07 | 0001193125-25-232514 | EDGAR | 2K words |
| 2025-08-14 | 0000950170-25-108426 | EDGAR | 2K words |
58 total filings indexed. 37 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001907108 |
| Ticker | LXEO |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.lexeotx.com |
| Listed | 2023-11-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/LXEO (~200 tokens, structured JSON with cryptographic provenance)